GlassScriptPhysician profile
Faraz Kerendi
NPI 1376727842
$906,135.57
in general payments reported to CMS, 2019-2025
35 companies · $72K in 2025
The $72K reported for 2025 was more than what 98% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116K · 2020: $67K · 2021: $140K · 2022: $186K · 2023: $190K · 2024: $136K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $303K · Travel and Lodging: $78K · Food and Beverage: $17K · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $302,694.10 |
| Travel and Lodging | $78,043.00 |
| Food and Beverage | $17,251.78 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $537,055.43 | 2019-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Abbott Laboratories | $152,230.05 | 2019-2025 | Tendyne, Epic, Mitraclip |
| Medical Device Business Services, INC. | $119,163.83 | 2022-2025 | Ethicon, Evarrest, Surgicel Nu-Knit |
| Ethicon US, LLC | $49,911.40 | 2019-2025 | Evarrest, Surgicel Nu-Knit, Ethicon |
| Medtronic, INC. | $16,467.37 | 2021-2025 | Corevalve Evolut R, Avalus, Simulus |
| Ethicon INC. | $9,838.48 | 2022-2025 | Ethicon, Surgicel Nu-Knit, Surgiflo Hemostatic Matrix |
| Medtronic Vascular, INC. | $9,658.70 | 2019-2020 | |
| Edwards Lifesciences Corporation | $3,750.41 | 2019-2025 | Sapien 3 Ultra Resilia |
| Livanova USA, INC. | $1,948.53 | 2019-2025 | Mics Cannulae |
| Elutia, INC. | $889.95 | 2019-2022 | |
| Bolton Medical INC | $543.66 | 2020-2025 | Thoraflex Hybrid, Gelweave, Access |
| Ancora Heart, INC. | $528.01 | 2019 | |
| Boston Scientific Corporation | $405.45 | 2019-2025 | Eluvia |
| Getinge USA Sales, LLC | $365.79 | 2020-2025 | Vasoview Hemopro 2 |
| Intuitive Surgical, INC. | $298.25 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $290.78 | 2024-2025 | Indigo System |
| Abiomed | $276.35 | 2019-2025 | |
| Cardiva Medical, INC. | $270.27 | 2024 | Other |
| Corcym INC | $218.05 | 2021-2022 | |
| Artivion, INC. | $201.24 | 2019 | |
| Lsi Solutions INC | $192.81 | 2019-2023 | Cor Knot, Ram |
| Cook Medical LLC | $191.28 | 2020-2025 | Cook, Zenith Alpha |
| Smith+Nephew, INC. | $172.72 | 2019 | |
| Core Surgical Group | $168.27 | 2025 | |
| Stryker Corporation | $166.67 | 2024 | N/A |
| Becton, Dickinson and Company | $153.71 | 2025 | Hemosphere |
| Shockwave Medical, INC | $142.62 | 2021-2025 | |
| Angiodynamics, INC. | $135.38 | 2022 | |
| Medinc of Texas | $133.36 | 2022 | |
| Bard Peripheral Vascular, INC. | $105.03 | 2019 | |
| Kci USA, INC. | $80.90 | 2022 | |
| W. L. Gore & Associates, INC. | $72.02 | 2024 | Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Silk Road Medical, INC. | $49.28 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Octapharma USA, INC. | $40.48 | 2025 | Fibryga |
| Opsens INC. | $19.04 | 2023 | Optowire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraz Kerendi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.